§ 610.42. Restrictions on use for further manufacture of medical devices.
155 words·~1 min read·
/us/cfr/t21/s§ 610.42·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)In addition to labeling requirements in subchapter H of this chapter, when a medical device contains human blood or a blood component as a component of the final device, and the human blood or blood component was found to be reactive by a screening test performed under § 610.40(a) and (b), then you must include in the device labeling a statement of warning indicating that the product was manufactured from a donation found to be reactive by a screening test for evidence of infection due to the identified relevant transfusion-transmitted infection(s).
(b)FDA may approve an exception or alternative to the statement of warning required in paragraph
(a)of this section based on evidence that the reactivity of the human blood or blood component in the medical device presents no significant health risk through use of the medical device. [66 FR 31164, June 11, 2001, as amended at 80 FR 29897, May 22, 2015]
Connections6 cite this
Cited by 6 sections
Citation graph
cites case law
§ 610.42
Restrictions on use for further manufacture of medical devices.
Fed. Reg.×6
Cites 0Cited by 6 across 1 source